CONVALESCENT PLASMA TO LIMIT CORONAVIRUS ASSOCIATED COMPLICATIONS

CONVALESCENT PLASMA TO LIMIT CORONAVIRUS ASSOCIATED COMPLICATIONS

Publication date: May 27, 2020

This is a randomized, blinded phase 2 trial to assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with a symptom onset between 3 and 7 days OR within 72 hours of hospitalization.

Concepts Keywords
Blood Abnormal imaging
Chest Pain Controlled trials pharmaceuticals
Congestive Heart Failure SARS
Contraindication ECMO
Coronavirus Mechanical ventilation
Cough Extracorporeal membrane oxygenation
DSMB Medicine
ECMO Medical specialties
Einstein Clinical medicine
Extracorporeal Membrane Oxygenation Intensive care medicine
Fever Respiratory therapy
Immunoglobulin RTT
IND Hematology
Mechanical Ventilation Transfusion medicine
Oxygen Extracorporeal membrane oxygenation
Oxygen Saturation Mechanical ventilation
Pharmaceuticals Oxygen therapy
Plasma
Protocol
Randomized Controlled Trials
Renal Failure
SARS
Symptom
Transfusion
Yale

Semantics

Type Source Name
disease MESH COMPLICATIONS
disease MESH chest pain
drug DRUGBANK Oxygen
disease MESH Contraindication
disease MESH congestive heart failure
disease MESH renal failure
disease MESH Coronavirus Infections

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *